GoGold Reports Quarterly Production at Parral of 406,150 Silver Equivalent Ounces

Shares Outstanding: 329,527,261 Trading Symbols: TSX: GGD OTCQX: GLGDF GoGold Resources Inc. (TSX: GGD)(OTCQX: GLGDF)(“GoGold”, “the Company”) is pleased to report production for the quarter ending September 30, 2024 of 406,150 silver equivalent ounces, consisting of 167,001 silver ounces, 2,232 gold ounces, 132 tonnes of copper, and 100 tonnes of zinc. https://mma.prnewswire.com/media/2530421/GoGold_Resources_Inc__GoGold_Reports_Quarterly_Production_at_Par.jpg “The quarter yielded […]

Nisun International to Report First Half 2024 Financial Results and Host Earnings Conference Call on Tuesday, October 15th

Nisun International Enterprise Development Group Co., Ltd. (“Nisun International” or the “Company”) (Nasdaq: NISN), a technology and industry driven integrated supply chain solutions provider, today announced that it will report its unaudited financial results for the first half of 2024 after the close of the market on Tuesday, October 15th at 4:15 pm New York

International Paper to Release Third-Quarter 2024 Earnings on October 31, 2024

International Paper (NYSE: IP) will release third-quarter 2024 earnings on October 31, 2024, before the opening of the New York Stock Exchange. https://mma.prnewswire.com/media/2012321/International_Paper__3_1_22_Logo.jpg The company will host a webcast to discuss earnings and current market conditions, beginning at 10 a.m. ET (9 a.m. CT). All interested parties are invited to listen to the webcast via

Cerro de Pasco Resources Reports Initial Assay Results from its Quiulacocha Tailings Drill Campaign

MONTRÉAL, Oct. 15, 2024 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (CSE: CDPR) (OTCPK: GPPRF) (FRA: N8HP) (“CDPR” or the “Company”) is pleased to report that its 40-hole, Phase 1 drilling program at the Quiulacocha Tailings Project (“QT Project”) is now nearing completion. Key Highlights Drillhole SPT04 intersected 19 meters at 1.91 Oz/t (59g/t)

BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) — BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni

One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry

LAS VEGAS, Nev., Oct. 15, 2024 (GLOBE NEWSWIRE) — One World Products, Inc. (the “Company”) (OTCQB: OWPC), a Nevada-based leader in sustainable industrial hemp solutions, recently showcased fully validated hemp-based molded containers – developed for an initial order of 1,400 units from Flex-N-Gate, a tier 1 supplier to the automotive industry. These production-ready reusable containers,

ZenaTech Announces First US Trial of the ZenaDrone IQ Nano Drone for Inventory Management by an Auto Parts Manufacturer

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, today announced that its subsidiary, ZenaDrone, has begun the first US trial of the IQ Nano product solution for inventory management, beginning with a multinational auto part and

Ocular Therapeutix(TM) Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI(TM) in Wet AMD

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and

Attovia Therapeutics Appoints Chief Financial Officer

FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ: CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a webinar, Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease, featuring Dr.

Scroll to Top